OR WAIT null SECS
MilliporeSigma surveyed 250 biopharmaceutical executives on how their companies will manage new risks associated with the changing biopharmaceutical landscape.
On May 24, 2016, MilliporeSigma released survey results of 250 global biopharmaceutical executives on how their companies will manage new risks associated with the changing biopharma landscape, the company said in a press announcement. The survey, which was sponsored by MilliporeSigma, was conducted by the Economist Intelligence Unit (EIU), a resource for economic and business research, forecasting, and analysis. MilliporeSigma presented the findings from the survey at the BIO International Convention, in San Francisco, California on June 8, 2016.
According to MilliporeSigma, among survey respondents, 48% said they are developing or will develop novel therapies such as gene and cell therapies. Approximately 80% of respondents are highly optimistic about their company’s ability to bring new drug products to market over the next five years. Companies also anticipate entering South Korea, Indonesia, and Taiwan over the next five years. Approximately 32% of respondents said that they think regulatory uncertainty may disrupt their company’s strategy in the next five years.
Among the 250 survey respondents, 31% are from Europe, 30% from North America, 29% from Asia, and 10% from other countries. Of these respondents, 50% were from biopharma companies with less than $500 million in revenue, while the other 50% consisted of larger companies.